Last reviewed · How we verify

Seretide

GlaxoSmithKline · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Seretide is a Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved. Also known as: salmeterol xinafoate and fluticasone propionate, Symbicort compared with Seretide.

Seretide is a medication used to manage asthma and Chronic Obstructive Pulmonary Disease (COPD). It contains a combination of fluticasone, a glucocorticoid receptor agonist, and salmeterol, a long-acting beta2-adrenergic agonist.

At a glance

Generic nameSeretide
Also known assalmeterol xinafoate and fluticasone propionate, Symbicort compared with Seretide
SponsorGlaxoSmithKline
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Seretide

What is Seretide?

Seretide is a Small molecule drug developed by GlaxoSmithKline.

Who makes Seretide?

Seretide is developed and marketed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

Is Seretide also known as anything else?

Seretide is also known as salmeterol xinafoate and fluticasone propionate, Symbicort compared with Seretide.

What development phase is Seretide in?

Seretide is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing